Patent ID: 6858607

Claim:
A compound of Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein: X is O, S or NR 6 , wherein R 6 is hydrogen or optionally substituted alkyl; Y is CN, COR 7 , CO 2 R 7 or CONR x R y , wherein R 7 , R x and R y are independently hydrogen, C 1-10 alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl; or R x and R y are taken together with the nitrogen to form a heterocycle; Z is NR 8 R 9 , NHCOR 8 , N(COR 8 ) 2 , N(COR 8 )(COR 9 ), N═CHOR 8 or N═CHR 8 , wherein R 8 and R 9 are independently H, C 1-4 alkyl or aryl, or R 8 and R 9 are combined together with the group attached to them to form a heterocycle; R 1 -R 2 are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C 1-10 alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol; R 5 is hydrogen or C 1-10 alkyl; A is optionally substituted and is aryl, heteroaryl, saturated carbocyclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic or arylalkyl; and B is optionally substituted and is a fused thiazole, oxazole, 2-imino-imidazole, 2,1,3-thiadiazo-2-one, thiazol-2-one, oxazol-2-one, oxazol-2-thione, imidazol-2-thione, thiazol-2-thione, imidazoline, oxazoline, thiazoline, triazole, oxazine, oxazine-2,3-dione, or piperazine ring.